Results 131 to 140 of about 1,653 (153)

Impacts of co-mutations in oligometastatic and oligoprogressive non-small cell lung cancer with <i>EGFR/ALK</i> mutations-a narrative review of the current literature. [PDF]

Transl Lung Cancer Res
Lim JU, Jang AL, Lee J, Park SY, An TJ, Sa YJ, Kim HR, Kim TJ, Kim BH, Park CK.   +9 more
europepmc   +1 more source

Local Ablative Therapy Followed by Osimertinib Rechallenge in Oligoprogressive, EGFR-Mutated NSCLC: A Phase 2 Study. [PDF]

JTO Clin Res Rep
Ghafoor A, Roper N, Kim C, Hoang CD, Kesarwala AH, Camphausen KA, Farouq K, Akoth E, Keen C, Szabo E, Bhageri H, Rajan A, Guha U.   +12 more
europepmc   +1 more source

Thermal ablation of breast cancer liver metastases achieves durable control and prolongs chemotherapy-free survival in selected patients

Ahmed N, Okines A, McGrath S, Parton M, Kipps E, Turner N, Johnston E, Johnston S, Fotiadis N.   +8 more
europepmc   +1 more source

SBRT for oligoprogressive oncogene addicted NSCLC

Lung Cancer, 2017
Lung cancer is one of the leading causes of cancer death in men and women and treatment outcome continues to lag behind other common cancer types. A subset of lung adenocarcinoma patients exhibit a somatic mutation in EGFR or an ALK rearrangement.
Matthias Guckenberger
exaly   +2 more sources

Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies [PDF]

Current Oncology Reports
Purpose of ReviewThis review discusses the definitions, treatment modalities, management, future directions, and ongoing clinical trials of oligoprogressive disease in oncogene-driven and non-oncogene-driven NSCLC.Recent FindingsDuring the last decades ...
Dirk De Ruysscher, Aakash P Desai, Lizza Hendriks   +2 more
exaly   +2 more sources

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Expert Review of Anticancer Therapy, 2020
Introduction: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than
Francesco Massari, Matteo Santoni, Maddalena Donini   +2 more
exaly   +2 more sources

Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives

Clinical and Experimental Metastasis
Metastatic breast cancer (MBC) is still an incurable disease, which eventually develops resistance mechanisms against systemic therapies. While most patients experience widespread disease progression during systemic treatment (ST), in some cases ...
Ugo De Giorgi, Michela Palleschi, Giandomenico di Menna   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer

European Urology Oncology, 2021
Samuel Denmeade, Kekoa Taparra, Phuoc T. Tran   +2 more
exaly